Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.

Seeking Alpha • 11 hours ago

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Sep 4, 2026

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Zacks Investment Research • Sep 4, 2026

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.

Zacks Investment Research • Sep 4, 2026

Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price

Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.

Seeking Alpha • Sep 4, 2026

Bristol Myers Squibb: Still Cheap, Despite What The Chart Says

Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.

Seeking Alpha • Sep 4, 2026

Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research

Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.

WSJ • Sep 3, 2026

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Technical indicators have turned bullish for the three stocks.

Barrons • Sep 3, 2026

This Popular Healthcare ETF Is Diluting Your Dividend Income

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

24/7 Wall Street • Aug 31, 2026

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and developing more to offset the revenue it will lose.

The Motley Fool • Aug 29, 2026